CN109172823A - A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic - Google Patents
A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic Download PDFInfo
- Publication number
- CN109172823A CN109172823A CN201811080058.6A CN201811080058A CN109172823A CN 109172823 A CN109172823 A CN 109172823A CN 201811080058 A CN201811080058 A CN 201811080058A CN 109172823 A CN109172823 A CN 109172823A
- Authority
- CN
- China
- Prior art keywords
- application
- aunps
- ciprofloxacin
- solution
- ultrasonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229960003405 ciprofloxacin Drugs 0.000 title claims abstract description 25
- 230000000694 effects Effects 0.000 title claims abstract description 18
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 239000010931 gold Substances 0.000 title claims abstract description 6
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 6
- 230000001737 promoting effect Effects 0.000 title claims description 4
- 238000002604 ultrasonography Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000009467 reduction Effects 0.000 claims abstract description 4
- 239000001509 sodium citrate Substances 0.000 claims abstract description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000736199 Paeonia Species 0.000 claims description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 claims 1
- 229910021505 gold(III) hydroxide Inorganic materials 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- 230000001408 fungistatic effect Effects 0.000 description 11
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- -1 hydroxyl radical free radical Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to sound power antimicrobial chemical therapies, belong to pharmaceutical technology field, the present invention discloses a kind of gold nano grain (AuNPs) and Ciprofloxacin combining ultrasonic is being promoted to inhibit the application on E. coli Activity, and AuNPs of the invention is prepared using traditional reduction of sodium citrate method.Apply ultrasound after AuNPs and Ciprofloxacin physical mixed, Ciprofloxacin can be enhanced to the inhibiting effect of Escherichia coli, effectively improve bacteriostasis rate, to reduce the dosage of antibiotic, promote the reasonable employment of antibiotic, alleviates abuse of antibiotics bring bacterial drug resistance problem.
Description
Technical field
The present invention relates to pharmaceutical technology fields, and in particular to gold nano grain (AuNPs) presses down Ciprofloxacin combining ultrasonic
The facilitation of E. coli Activity processed.
Background technique
The abuse of antibiotic causes great threat to the mankind, and drug tolerant bacteria is worldwide spread rapidly,
Therefore need to establish a kind of safe and efficient method to antimicrobial agent, so that the mankind be made to avoid the harm by drug-fast bacteria.Sound is dynamic
Resist strenuously bacterium chemotherapy have been developed in recent years confrontation multi-drug resistant bacteria new method, this method using ultrasonic wave have compared with
The characteristics of strong penetration into tissue, is gathered in the sound sensitiser of illing tissue using ultrasonic irradiation, generates activity by activation sound sensitiser
Oxygen and its a series of phonochemical reactions or physical action of induction reach killing microorganism purpose.
In recent years, the booming large-scale development for having driven nano material of nanosecond science and technology and application, are especially being cured
Medicine field shows unique advantage.With the further investigation to nano material, it is found that nano particle can both reduce ultrasonic sky
Change threshold value, the i.e. minimum pressure of Cavitation inciption, and may additionally facilitate the generation of hydroxyl radical free radical in system, and then plays enhancing suppression
The effect of bacterium effect.AuNPs itself small toxicity, good biocompatibility, Small side effects are used for antineoplaston by safety.
Studies have shown that Ciprofloxacin is other than itself as antibiotic usage, also there is sound photodynamic activity, by its with it is super
Sound is used in combination, and can enhance its inhibition to Escherichia coli Growth.After AuNPs is added in drug solution and applies ultrasound,
Ultrasound cavitation effect and the quick property of Ciprofloxacin itself sound can be enhanced by AuNPs, it is super that AuNPs significantly increases Ciprofloxacin joint
The fungistatic effect of sound.
Summary of the invention
It is an object of the invention to study AuNPs to the facilitation of Ciprofloxacin combining ultrasonic bacteriostatic activity, this method
The sensibility that Escherichia coli can be effectively improved inhibits its growth, and can effectively facilitate the reasonable employment of antibiotic.
To achieve the goals above, the technical scheme adopted by the invention is that:
A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic.
Ciprofloxacin, AuNPs, E.coli and physiological saline are specially sequentially added in centrifuge tube and are mixed by the application
It closes, centrifuge tube is put into ultrasound system and is ultrasonically treated；After ultrasonic treatment, solution is taken to be placed in solid culture primary surface, moved
Enter to be inverted culture 18h in 37 DEG C of incubators, carry out bacterium colony counting later and calculates bacteriostasis rate.
The application, Ciprofloxacin Concentration is 2.5 × 10 in the ultrasound system-5~7.5 × 10-5mg/mL。
The application, AuNPs solution concentration is 2.5 × 10 in the ultrasound system-4mg/mL。
The application, e. coli concentration is 1 × 10 in the ultrasound system7cfu/mL。
The application, ultrasonic time is 15-45min in the ultrasound system.
The application, ultrasonic power is 450W, supersonic frequency 40kHz, ultrasonic temperature 20 in the ultrasound system
DEG C~37 DEG C.
The application, the AuNPs are prepared by traditional reduction of sodium citrate method, average grain diameter 18nm.
The application, the AuNPs's is specific the preparation method comprises the following steps: aqueous solution of chloraurate is placed in three-necked bottle, oil bath
It is heated to reflux, after waiting aqueous solution of chloraurate to boil, citric acid three sodium solution is added rapidly in aqueous solution of chloraurate；Solution from
Purple slowly becomes red, waits solution to become peony and continues the 5min that flows back, removes heat source later and cool down at room temperature, by solution
It is closed to be transferred to glass sample bottle, is saved in 4 DEG C of refrigerators, obtains AuNPs solution.
The application, the aqueous solution of chloraurate concentration are 1.0 × 10-3The concentration of mol/L, citric acid three sodium solution is
3.38×10-2mol/L。
The invention has the following advantages:
AuNPs of the present invention inhibits E. coli Activity to have apparent facilitation Ciprofloxacin combining ultrasonic.The present invention
The characteristic that biological membrane permeability can be changed using the cavitation effect that ultrasonic radiation generates, promotes more drugs to enter cells play
Lethal effect.As the addition AuNPs in solution, ultrasonic cavitation core site can be used as, enhance the cavitation effect of ultrasound,
It can promote to generate more free radicals in system simultaneously, and cause a series of phonochemical reactions, to play enhancing drug to thin
Bacterium lethal effect.The present invention cooperates with antibacterial facilitation to Ciprofloxacin combining ultrasonic using AuNPs, greatly reduces antibacterial
The usage amount of antibiotic in the process, to achieve the purpose that rationally to utilize antibiotic.
Detailed description of the invention
Fig. 1 is the influence that 2 Ciprofloxacin Concentration of embodiment promotes AuNPs its supersonic synergic fungistatic effect.
Fig. 2 is the influence that 3 ultrasonic time of embodiment promotes AuNPs Ciprofloxacin and supersonic synergic fungistatic effect.
Fig. 3 is the influence that 4 ultrasonic temperature of embodiment promotes AuNPs Ciprofloxacin supersonic synergic fungistatic effect.
Specific embodiment
Technical solution of the present invention is described in detail below by specific example.
Embodiment 1: the preparation of nanogold
AuNPs is prepared using traditional trisodium citrate reduction method in the present invention.All glasswares must all use king
Water uses deionized water repeated flushing after impregnating 30min.The preparation process of AuNPs is as follows: taking 40mL concentration is 1.0 × 10- 3The aqueous solution of chloraurate of mol/L is placed in 100mL three-necked bottle, and oil bath heating reflux will be dense after waiting aqueous solution of chloraurate to boil
Degree is 3.38 × 10-2The 4mL citric acid three sodium solution of mol/L is added rapidly in aqueous solution of chloraurate.Solution from purple slowly
Become red, waits aqueous solutions to become peony and continue the 5min that flows back, remove heat source later and cool down at room temperature, solution is transferred to
20mL glass sample bottle is closed, saves in 4 DEG C of refrigerators, and AuNPs solution theory concentration obtained by this method is 0.2mg/mL.With ultraviolet point
The detection of light photometer, characteristic peak positions are in 520nm or so, it was demonstrated that AuNPs is successfully made.
Embodiment 2: Ciprofloxacin Concentration promotes AuNPs the influence of its supersonic synergic fungistatic effect
9 5mL are taken to connect lid centrifuge tube, packet is tightened with cotton cord again with brown paper.9 empty conical flasks are taken, are sealed respectively with tampon
Good bottleneck, brown paper are tightened with cotton thread again after wrapping up.Physiological saline 150mL is taken, loaded in 250mL conical flask, takes a 10mL
The effective brown paper of liquid relief wrap.It will be stand-by after 121 DEG C of high pressure steam sterilization 15min of the above article.Super-clean bench ultraviolet sterilization
After 30min, tested around the alcolhol burner lighted.Under aseptic condition, after centrifuge tube is marked, by table 1 toward centrifuge tube
Middle sample-adding.No. 1-8 sample-adding centrifuge tube of number is put into progress ultrasonic irradiation 30min in ultrasonic cleaner, controls ultrasonic procedure
Water temperature is 20 DEG C, and water level is controlled in 70mm, and No. 0 sample-adding centrifuge tube of number is placed under the conditions of 20 DEG C of dark place.
After ultrasound, the 100 above-mentioned sample solutions of μ L are drawn respectively, are moved into the conical flask equipped with 9.9mL physiological saline, are shaken
It is even, then therefrom draw 100 μ L solution respectively and be placed in solid culture primary surface, it is smoothened with glass rake, marks and move into 37 again
It is inverted culture 18h in DEG C incubator, carries out bacterium colony counting later and simultaneously calculates bacteriostasis rate.
The sample that 1 Ciprofloxacin Concentration of table influences experiment to joint fungistatic effect dispenses table
Experimental result is as shown in Figure 1.Individually ultrasound itself can have certain inhibiting effect to bacterium, be somebody's turn to do after AuNPs is added
Effect enhancing；As drug concentration increases, bacteriostasis rate is gradually risen；Under identical drug concentration, the group bacteriostasis rate containing AuNPs
It is apparently higher than pure medicine group, illustrates that the presence of AuNPs can promote the ultrasonic fungistatic effect to Escherichia coli of Ciprofloxacin collaboration,
But its facilitation effect is continued growing with drug concentration, will be no longer so obvious.
Embodiment 3: ultrasonic time promotes AuNPs the influence of its combining ultrasonic fungistatic effect
With 2 preparing experiment articles of embodiment and sterilization treatment is carried out, is loaded by table 2 into centrifuge tube.
The sample that 2 ultrasonic time of table influences experiment to joint fungistatic effect dispenses table
Except 0,1,5 group of remaining group is put into the time ultrasound in ultrasonic cleaner by design.Control ultrasonic procedure water
Temperature is 20 DEG C, and water level is controlled in 70mm.0,1, No. 5 is placed under the conditions of 20 DEG C of dark place.With 2 step of embodiment, dilution after ultrasound
After apply ware, move into 37 DEG C of incubators and be inverted culture 18h, carry out bacterium colony counting later and simultaneously calculate bacteriostasis rate.
Experimental result is as shown in Figure 2.Drug itself has certain inhibiting effect to Escherichia coli, and the work after nanogold is added
With enhancing；With the extension of ultrasonic time, the antibacterial effect enhancing of drug collaboration ultrasound was positively correlated, and identical with the time
Ultrasonic time, the group bacteriostasis rate containing AuNPs is apparently higher than pure medicine group, illustrates that AuNPs can promote drug collaboration ultrasound
It is antibacterial, and its facilitation becomes strong with the extension of ultrasonic time.
Embodiment 4: ultrasonic temperature promotes AuNPs the influence of its supersonic synergic fungistatic effect
With 2 preparing experiment articles of embodiment and sterilization treatment is carried out, is loaded by table 3 into centrifuge tube.
The sample that 3 ultrasonic temperature of table influences experiment to joint fungistatic effect dispenses table
No. 1-4 above-mentioned sample-adding centrifuge tube is put into ultrasound 30min in ultrasonic cleaner, controls No. 1 and No. 2 ultrasonic procedure water
It is 37 DEG C that temperature, which is 20 DEG C, No. 3 and No. 4 ultrasonic procedure water temperatures, and water level is controlled in 70mm.No. 0 sample-adding centrifuge tube is placed in dark place 20
Under the conditions of DEG C.With 2 step of embodiment after ultrasound, ware is applied after dilution, moves into 37 DEG C of incubators and is inverted culture 18h, carry out later
Bacterium colony counts and calculates bacteriostasis rate.
For experimental result as shown in figure 3, under same temperature, drug alone combining ultrasonic shows certain bacteriostasis, contains
There is the bacteriostasis rate of AuNPs to be higher than pure medicine group；As ultrasonic temperature increases, two groups of bacteriostasis rate is all increased, and containing AuNPs's
Group bacteriostasis rate is still higher than pure medicine group, illustrates that the raising of ultrasonic temperature can promote AuNPs to cooperate with ultrasound suppression to Ciprofloxacin
The effect of bacterium.
Claims (10)
1. a kind of gold nano grain is promoting the application on Ciprofloxacin combining ultrasonic inhibition E. coli Activity.
2. application as described in claim 1, which is characterized in that be specially by Ciprofloxacin, AuNPs, E.coli and physiology salt
Water is sequentially added in centrifuge tube and is mixed, and centrifuge tube is put into ultrasound system and is ultrasonically treated；After ultrasonic treatment, solution is taken to set
It in solid culture primary surface, moves into 37 DEG C of incubators and is inverted culture 18h, carry out bacterium colony counting later and calculate bacteriostasis rate.
3. application as claimed in claim 2, which is characterized in that Ciprofloxacin Concentration is 2.5 × 10 in the ultrasound system-5~
7.5×10-5mg/mL。
4. application as claimed in claim 2, which is characterized in that AuNPs solution concentration is 2.5 × 10 in the ultrasound system- 4mg/mL。
5. application as claimed in claim 2, which is characterized in that e. coli concentration is 1 × 10 in the ultrasound system7cfu/
mL。
6. application as claimed in claim 2, which is characterized in that ultrasonic time is 15-45min in the ultrasound system.
7. application as claimed in claim 2, which is characterized in that ultrasonic power is 450W, supersonic frequency in the ultrasound system
For 40kHz, ultrasonic temperature is 20 DEG C~37 DEG C.
8. application as described in claim 1, which is characterized in that the AuNPs is prepared by traditional reduction of sodium citrate method,
Average grain diameter is 18nm.
9. application as claimed in claim 8, which is characterized in that the AuNPs's is specific the preparation method comprises the following steps: gold chloride is water-soluble
Liquid is placed in three-necked bottle, and citric acid three sodium solution is added rapidly to chlorine after waiting aqueous solution of chloraurate to boil by oil bath heating reflux
In auric acid aqueous solution；Solution slowly becomes red from purple, waits solution to become peony and continues the 5min that flows back, removes heat source later
It cools down at room temperature, it is closed that solution is transferred to glass sample bottle, saves in 4 DEG C of refrigerators, obtains AuNPs solution.
10. application as claimed in claim 9, which is characterized in that the aqueous solution of chloraurate concentration is 1.0 × 10-3Mol/L,
The concentration of citric acid three sodium solution is 3.38 × 10-2mol/L。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811080058.6A CN109172823A (en) | 2018-09-17 | 2018-09-17 | A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811080058.6A CN109172823A (en) | 2018-09-17 | 2018-09-17 | A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109172823A true CN109172823A (en) | 2019-01-11 |
Family
ID=64911367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811080058.6A Pending CN109172823A (en) | 2018-09-17 | 2018-09-17 | A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109172823A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209842A (en) * | 2022-01-21 | 2022-03-22 | 辽宁大学 | Application of quinolone medicine combined with ultrasound in inhibition of helicobacter pylori |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103357887A (en) * | 2013-07-01 | 2013-10-23 | 西安交通大学 | Sea urchin-shaped hollow gold and silver alloy nano particle and preparation method and application thereof |
| EP3035648A1 (en) * | 2014-12-19 | 2016-06-22 | Alcatel Lucent | Determining dynamic user attributes using dynamic host configuration protocol |
-
2018
- 2018-09-17 CN CN201811080058.6A patent/CN109172823A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103357887A (en) * | 2013-07-01 | 2013-10-23 | 西安交通大学 | Sea urchin-shaped hollow gold and silver alloy nano particle and preparation method and application thereof |
| EP3035648A1 (en) * | 2014-12-19 | 2016-06-22 | Alcatel Lucent | Determining dynamic user attributes using dynamic host configuration protocol |
Non-Patent Citations (4)
| Title |
|---|
| AMENEH SAZGARNIA ET AL: "Therapeutic Effects of Acoustic Cavitation in the Presence of Gold Nanoparticles on a Colon Tumor Model", 《J ULTRASOUND MED》 * |
| SMRUTIREKHA SATAPATHY ET AL: "Biogenic synthesis and characterization of silver nanoparticles and their effects against bloom-forming algae and synergistic effect with antibiotics against fish pathogenic bacteria", 《J APPL PHYCOL》 * |
| 孔猛 等: "纳米金粒子对裸鼠胃癌组织近红外光谱范围的组织光学特性影响", 《光学学报》 * |
| 曹晓丽 等: "纳米技术在声/光动力抗菌化学疗法中的应用进展", 《国际药学研究杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209842A (en) * | 2022-01-21 | 2022-03-22 | 辽宁大学 | Application of quinolone medicine combined with ultrasound in inhibition of helicobacter pylori |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Near-infrared light II-assisted rapid biofilm elimination platform for bone implants at mild temperature | |
| Yan et al. | Gold nanoplates with superb photothermal efficiency and peroxidase-like activity for rapid and synergistic antibacterial therapy | |
| DK3051951T3 (en) | MODIFIED SURFACE capable of having bacteriostatic and bactericidal activity, the method of obtaining it and its use | |
| CN110393159B (en) | Egg cleaning and disinfecting method based on ultrasonic-micro nano bubble technology | |
| CN109172823A (en) | A kind of gold nano grain inhibits the application on E. coli Activity promoting Ciprofloxacin combining ultrasonic | |
| EP3881942A1 (en) | Plasma coating treatment method for inhibiting biological pathogen transfer | |
| Karau et al. | In vitro activity of the Qoustic Wound Therapy System against planktonic and biofilm bacteria | |
| CN104430639B (en) | The purposes of composition in the medicament of sterilizing for the preparation of blood station | |
| CN108853500A (en) | A kind of gold nano grain inhibits the application on E. coli Activity promoting piroxicam combining ultrasonic | |
| CN115634290A (en) | Bacterial cellulose composite membrane with photo-thermal-photodynamic synergistic antibacterial activity and preparation method thereof | |
| CN106619712B (en) | Application of the copper oxide-platinum nano complex in antibiosis | |
| CN114209842B (en) | Application of quinolone drugs combined with ultrasound in inhibiting helicobacter pylori | |
| CN109550048B (en) | Application of phenol safranine-mediated sonodynamic antibacterial chemotherapy in inhibiting activity of staphylococcus aureus | |
| CN202933254U (en) | Fumigation disinfection box for infectious diseases | |
| CN112878045A (en) | Air-permeable hydrophilic antibacterial antiviral medical cloth containing iodine compound | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN109464666A (en) | Phenol safranine and supersonic synergic inhibit the application of Escherichia coli | |
| CN107375966A (en) | A kind of irradiation sterilization method of Sterilized sanitation towel | |
| CN109526981A (en) | A kind of nanocomposite g-C3N4/ Ni and the preparation method and application thereof | |
| CN106806367A (en) | A kind of pharmaceutical composition for treating infections after burn | |
| CN113842481B (en) | Ultraviolet sterilization synergist lime essential oil and application thereof | |
| CN109528768B (en) | Nano bacteriostatic preparation for treating equine endometritis and preparation method thereof | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105395538A (en) | Medicine composition treating acute upper respiratory infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190111 |